KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Other Gross PP&E Adjustments (2016 - 2026)

TherapeuticsMD filings provide 16 years of Other Gross PP&E Adjustments readings, the most recent being -$5.1 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 18.84% to -$5.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$5.1 million, a 18.84% increase, with the full-year FY2025 number at -$5.3 million, up 13.26% from a year prior.
  • Other Gross PP&E Adjustments hit -$5.1 million in Q1 2026 for TherapeuticsMD, up from -$5.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$4.2 million in Q3 2022 to a low of -$7.1 million in Q1 2024.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$5.3 million (2025), compared with a mean of -$5.5 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 58.64% in 2022 and later plummeted 37.82% in 2024.
  • TherapeuticsMD's Other Gross PP&E Adjustments stood at -$5.1 million in 2022, then crashed by 33.89% to -$6.8 million in 2023, then rose by 9.88% to -$6.1 million in 2024, then increased by 13.26% to -$5.3 million in 2025, then rose by 4.36% to -$5.1 million in 2026.
  • The last three reported values for Other Gross PP&E Adjustments were -$5.1 million (Q1 2026), -$5.3 million (Q4 2025), and -$5.6 million (Q3 2025) per Business Quant data.